Cytokinetics Q4 Loss Widens to $1.50 vs Est. $1.48, Revenue Soars 356%
Cytokinetics posted a Q4 GAAP loss of $1.50 per share, missing the consensus of $1.48 and widening from a $1.26 loss a year earlier. Revenue reached $17.76 million, exceeding estimates by 356% and up 4.9% year-over-year.
1. Q4 Financial Results
Cytokinetics reported a GAAP loss of $1.50 per share in Q4 2025, slightly below the $1.48 consensus and wider than last year’s $1.26 loss after adjusting for non-recurring items. Revenue rose to $17.76 million from $16.93 million a year earlier, surpassing estimates by 356% and marking its second revenue beat in four quarters.
2. Year-to-Date Performance
Since January 1, 2026, shares have climbed 7.4% while the S&P 500 has slipped 0.1%, suggesting investor enthusiasm driven by the outsized revenue surprise despite the EPS miss.
3. Consensus Outlook
Analysts forecast a Q1 loss of $1.63 per share on $9.07 million in revenues and a full-year loss of $6.17 on $117.37 million, with future stock movement likely hinging on revisions to these estimates.